Gilead Sciences (1GILD) Financial Statements
Gilead Sciences Financial Overview
Gilead Sciences's market cap is currently $188.86B. The company's EPS TTM is $-3.10; its P/E ratio is -55.06; and it has a dividend yield of 1.81%. Gilead Sciences is scheduled to report earnings on February 4, 2027, and the estimated EPS forecast is $1.24. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 29.44B | $ 28.75B | $ 27.12B | $ 27.28B | $ 27.30B |
| Gross Profit | $ 23.21B | $ 22.50B | $ 20.62B | $ 21.62B | $ 20.70B |
| Operating Income | $ 11.70B | $ 1.66B | $ 7.61B | $ 7.33B | $ 9.92B |
| EBITDA | $ 13.58B | $ 4.43B | $ 10.50B | $ 8.85B | $ 11.33B |
| Net Income | $ 8.51B | $ 480.00M | $ 5.67B | $ 4.59B | $ 6.22B |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 9.61B | $ 11.57B | $ 7.26B | $ 6.38B | $ 6.52B |
| Total Assets | $ 59.02B | $ 58.99B | $ 62.13B | $ 63.17B | $ 67.95B |
| Total Debt | $ 24.94B | $ 26.71B | $ 24.99B | $ 25.23B | $ 26.70B |
| Net Debt | $ 17.37B | $ 16.72B | $ 18.90B | $ 19.82B | $ 21.36B |
| Total Liabilities | $ 36.41B | $ 39.75B | $ 39.38B | $ 41.96B | $ 46.89B |
| Stockholders' Equity | $ 22.70B | $ 19.33B | $ 22.83B | $ 21.24B | $ 21.07B |
| Cash Flow | |||||
| Free Cash Flow | $ 9.46B | $ 10.30B | $ 7.42B | $ 8.34B | $ 10.80B |
| Operating Cash Flow | $ 10.02B | $ 10.83B | $ 8.01B | $ 9.07B | $ 11.38B |
| Investing Cash Flow | $ -4.79B | $ -3.45B | $ -2.27B | $ -2.47B | $ -3.13B |
| Financing Cash Flow | $ -7.75B | $ -3.43B | $ -5.13B | $ -6.47B | $ -8.88B |
Currency in USD